<div id="readability-page-1"><p>Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) VP Maria Dobek sold 1,462 shares of the business's stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $13.73, for a total transaction of $20,073.26. Following the completion of the transaction, the vice president owned 15,373 shares in the company, valued at approximately $211,071.29. This trade represents a 8.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at the SEC website.</p><div><p><span></span><span>Get <strong>Janux Therapeutics</strong> alerts:</span></p></div><h2>Janux Therapeutics Stock Performance</h2><p>Janux Therapeutics stock traded down $0.15 during trading hours on Friday, hitting $13.65. 1,533,974 shares of the stock were exchanged, compared to its average volume of 2,182,684. The stock has a market capitalization of $821.05 million, a P/E ratio of -8.13 and a beta of 2.88. The business's 50-day moving average is $22.51 and its two-hundred day moving average is $23.74. Janux Therapeutics, Inc. has a 12 month low of $13.52 and a 12 month high of $61.59. </p><p>Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its earnings results on Thursday, November 6th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.21. The business had revenue of $10.00 million during the quarter, compared to analyst estimates of $3.07 million.  On average, equities analysts predict that  Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year. </p><h2>Analyst Upgrades and Downgrades</h2><p>A number of analysts have recently weighed in on the company. Barclays lowered their target price on Janux Therapeutics from $48.00 to $29.00 and set an &#34;overweight&#34; rating for the company in a research note on Wednesday, December 17th. Stifel Nicolaus lowered their price objective on shares of Janux Therapeutics from $46.00 to $38.00 and set a &#34;buy&#34; rating for the company in a research report on Tuesday, December 2nd. Wall Street Zen upgraded shares of Janux Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, November 8th. Bank of America decreased their price target on shares of Janux Therapeutics from $58.00 to $49.00 and set a &#34;buy&#34; rating on the stock in a research note on Tuesday, December 2nd. Finally, Cantor Fitzgerald lowered their price target on shares of Janux Therapeutics from $200.00 to $150.00 and set an &#34;overweight&#34; rating for the company in a report on Tuesday, December 2nd. Twelve research analysts have rated the stock with a Buy rating, two have given a Hold rating and one  has given a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $61.08.</p><p><b>Check Out Our Latest Analysis on Janux Therapeutics</b></p><h2>Hedge Funds Weigh In On Janux Therapeutics</h2><p>A number of hedge funds and other institutional investors have recently bought and sold shares of JANX. Walleye Capital LLC bought a new position in  Janux Therapeutics in the first quarter valued at approximately $307,000.  MetLife Investment Management LLC lifted its stake in shares of  Janux Therapeutics by 7.9% in the 1st quarter. MetLife Investment Management LLC now owns 18,663 shares of the company's stock valued at $504,000 after purchasing an additional 1,365 shares during the period.  Corebridge Financial Inc. lifted its stake in shares of  Janux Therapeutics by 11.2% in the 1st quarter. Corebridge Financial Inc. now owns 15,495 shares of the company's stock valued at $418,000 after purchasing an additional 1,555 shares during the period.  Cubist Systematic Strategies LLC boosted its position in shares of  Janux Therapeutics by 88.0% in the 1st quarter. Cubist Systematic Strategies LLC now owns 75,860 shares of the company's stock worth $2,048,000 after purchasing an additional 35,511 shares during the last quarter.  Finally, Alyeska Investment Group L.P. grew its stake in shares of  Janux Therapeutics by 18.5% during the first quarter. Alyeska Investment Group L.P. now owns 408,678 shares of the company's stock worth $11,034,000 after purchasing an additional 63,762 shares during the period. 75.39% of the stock is owned by institutional investors. </p><h2>About Janux Therapeutics</h2> (Get Free Report)<p>Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX. </p><p>Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Janux Therapeutics</li><li>But this $2 Gold Stock Before May 20, 2026</li><li>The $100 Trillion AI Story No One Is Telling You</li><li>Bombshell Exposé on China Strikes</li><li>Do not delete, read immediately</li><li>The Crash Has Already Started (Most Just Don’t See It Yet)</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SkFOWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SkFOWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Janux Therapeutics Right Now?</h2><p>Before you consider Janux Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Janux Therapeutics wasn't on the list.</p><p>While Janux Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

JANX

<p>Janux Therapeutics VP Maria Dobek sold 1,462 shares at $13.73 each, totaling $20,073.26, representing an 8.68% decrease in her ownership. Post-sale, she holds 15,373 shares valued at approximately $211,071.29. The transaction was disclosed to the SEC. The stock traded down to $13.65, with a market cap of $821.05 million. Analysts have recently adjusted target prices, with a consensus rating of "Moderate Buy" and a target of $61.08. Institutional investors own 75.39% of the stock.</p>

Janux Therapeutics (NASDAQ:JANX) VP Maria Dobek Sells 1,462 Shares